Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients

Fig. 1

Heterogeneity of CD27/CD117 expression subgroups across prognostic stratification systems and treatment response in multiple myeloma. A ISS stage, B DS stage, C Mayo MASS stage, D PI-based regimens Short-term treatment response (post-4-cycle chemotherapy); E IMiD-based or Mb-combination regimens Short-term treatment response (post-4-cycle chemotherapy); F ASCT regimens Short-term treatment response (post-transplant). *P < 0.05, **P < 0.01 and ***P < 0.001 indicating significant difference among groups

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us